The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Unattributed VC | Alive

Total Raised


Last Raised

$1.17M | 9 yrs ago

About UroSens

UroSens is developing diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. The Company has a worldwide exclusive license, from Cancer Research Technology, for the exploitation of MCM cancer biomarkers in the diagnosis of bladder and prostate cancer, using quantitative immunoassays. MCM proteins are excellent biomarkers, being directly involved in cell replication and are shed into urine by both prostate and bladder tumours. The ubiquitous nature of MCMs, and their direct involvement in cell replication, means that the Company can develop a single test format that works for both conditions.

UroSens Headquarter Location

Babraham Research Campus Babraham

Cambridge, England, CB22 3AT,

United Kingdom

+44 (0)1223 836 556

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing UroSens

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

UroSens is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest UroSens News

Prostate cancer pee test to launch this year

Mar 12, 2015

Published in Medtech A company aiming to replace the uncomfortable and invasive biopsies used to detect prostate and bladder cancer with a simple urine test expects to launch its first product this year following the closure of a £2 million funding round. The investment will be used to expand Urosens’ commercial and technical teams, finalise product development and begin to commercialise its diagnostic test, the UroSens Mcm5-ELISA, for prostate and bladder cancer. The new test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK. It focuses on Mcm5 (minichromosome maintenance complex component 5), a protein which only appears when cells divide, and is regarded as an excellent marker for the presence of dividing cancer cells. Urosens is also seeking to undertake further clinical trials in Europe and the United States to expand the applications of the Mcm5 test. In addition, UroSens will continue the development of a Point-of-Care version of the Mcm5 test. Dr Ian Campbell, CEO at UroSens, commented: "This investment round will enable us to expand our team and bring our novel assay to the market, providing patients with a simple non-invasive test for both bladder and prostate cancer. " Urosens raised £530k in equity investment in June 2013.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.